15 Best Biotech Penny Stocks to Invest in Right Now

Page 3 of 13

11. Relmada Therapeutics, Inc. (NASDAQ:RLMD)

Year-to-Date Return: 194.23% 

Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotech company developing innovative therapies for oncology and central nervous system (CNS) disorders. In 2025, the company will expand its pipeline with two Phase 2 candidates: NDV-01 for non-muscle invasive bladder cancer (NMIBC) and sepranolone for compulsivity disorders such as Prader-Willi Syndrome (PWS).

In September 2025, Relmada Therapeutics, Inc. (NASDAQ:RLMD) reported promising Phase 2 results for NDV-01, a sustained-release formulation of gemcitabine and docetaxel, showing a 91% complete response rate. The firm is preparing to launch a Phase 3 registrational trial in early 2026. Sepranolone is also progressing toward a Phase 2 trial for PWS, with regulatory and manufacturing steps underway. Additionally, the business regained compliance with Nasdaq’s minimum bid price requirement, ensuring continued listing and signaling market stability, placing it among the best penny stocks to watch in biotech.

On the financial side, Relmada Therapeutics, Inc. (NASDAQ:RLMD) posted a $9.9 million net loss in Q2 2025 and held approximately $20.6 million in cash, reflecting a cautious cash position as it ramps up for larger clinical trials.

Page 3 of 13